FLT3-IN-14

Modify Date: 2024-01-16 18:40:55

FLT3-IN-14 Structure
FLT3-IN-14 structure
Common Name FLT3-IN-14
CAS Number 2620551-45-1 Molecular Weight 472.56
Density N/A Boiling Point N/A
Molecular Formula C25H24N6O2S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of FLT3-IN-14


FLT3-IN-14 is a potent FLT3 inhibitor with IC50s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model[1].

 Names

Name FLT3-IN-14

 FLT3-IN-14 Biological Activity

Description FLT3-IN-14 is a potent FLT3 inhibitor with IC50s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model[1].
Related Catalog
Target

IC50: 1.4 nM (FLT-ITD), 5.6 nM (FLT3-WT)[1]

In Vitro FLT3-IN-14 (compound 9c) (0-10 μM; 24 hours) inhibits the proliferation of tested twelve haematological cell lines with IC50s of 0.011-1.582 μM[1]. FLT3-IN-14 (0-10 μM; 72 hours) exhibits low toxicity, with GI50 greater than 10 μM, in resting lymphocytes[1]. FLT3-IN-14 (1-50 nM; 24 and 48 hours) accumulates annexin-V positive cells in a concentration and time-dependent manner[1]. FLT3-IN-14 (25-100 nM; 24 and 48 hours) induces a significant G1 arrest in both cell lines[1]. FLT3-IN-14 (1-50 nM; 24 hours) induces the dephosphorylation of FLT3[1]. Cell Proliferation Assay Cell Line: MOLT-4 , HL-60, KG-1, KG-1a, MOLM-13, MV4-11, NOMO-1, OCI-AML2, PL-21, THP-1, K-562, KCL-22[1] Concentration: 0-10 μM Incubation Time: 24 hours Result: Inhibited the proliferation of these twelve haematological cell lines with IC50s of 0.011-1.582 μM. Cell Cytotoxicity Assay Cell Line: PBL[1] Concentration: 0-10 μM Incubation Time: 72 hours Result: Exhibited low toxicity, with GI50 greater than 10 μM, in resting lymphocytes. Apoptosis Analysis Cell Line: MV4-11[1] Concentration: 1, 10 and 50 nM Incubation Time: 24 and 48 hours Result: Accumulated annexin-V positive cells in a concentration and time-dependent manner. Cell Cycle Analysis Cell Line: MOLM-13 and MV-14[1] Concentration: 25, 50, 75 and 100 nM Incubation Time: 24 and 48 hours Result: Induced a significant G1 arrest in both cell lines. Western Blot Analysis Cell Line: MV-14[1] Concentration: 1, 10 and 50 nM Incubation Time: 24 hours Result: Induced the dephosphorylation of FLT3.
In Vivo FLT3-IN-14 (1.0 and 3.0 mg/kg; IP; daily for 28 days) significantly reduces tumor growth in a dose-dependent manner without sign of toxicity[1]. Animal Model: NOD/SCID female mice (subcutaneously implanted MV4-11)[1] Dosage: 1.0 and 3.0 mg/kg Administration: IP; daily for 28 days Result: Significantly reduced tumor growth by 44.1% and 55.2% at 1 and 3 mg/kg, respectively.
References

[1]. Cilibrasi V, Spanò V, Bortolozzi R, et al. Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations. Eur J Med Chem. 2022;235:114292.

 Chemical & Physical Properties

Molecular Formula C25H24N6O2S
Molecular Weight 472.56
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.